Which has better earnings and valuation, CADL or ADAG?

Adagene has higher revenue and earnings than Candel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A Adagene $7.67M 22.30 -$17.61M N/A N/A

Is CADL or ADAG more profitable?

Adagene's return on equity of 0.00% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Adagene N/A N/A N/A

Which has preferable earnings & valuation, AURA or ADAG?

Adagene has higher revenue and earnings than Aura Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Adagene $7.67M 22.30 -$17.61M N/A N/A

Is AURA or ADAG more profitable?

Adagene's return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Adagene N/A N/A N/A

Which has stronger valuation & earnings, ALLO or ADAG?

Adagene has higher revenue and earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 31,926.38 -$190.89M -$0.77 N/A Adagene $7.67M 22.30 -$17.61M N/A N/A

Is ALLO or ADAG more profitable?

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Adagene N/A N/A N/A

Which has stronger earnings and valuation, PRME or ADAG?

Adagene has higher revenue and earnings than Prime Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prime Medicine $4.63M 135.37 -$201.14M -$1.23 N/A Adagene $7.67M 22.30 -$17.61M N/A N/A

Which has higher earnings and valuation, CRMD or ADAG?

CorMedix has higher revenue and earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 2.08 $163.05M $2.13 3.88 Adagene $7.67M 22.30 -$17.61M N/A N/A

Is CRMD or ADAG more profitable?

CorMedix has a net margin of 45.25% compared to Adagene's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Adagene's return on equity. Company Net Margins Return on Equity Return on Assets CorMedix 45.25% 45.57% 24.76% Adagene N/A N/A N/A

Adagene (ADAG) Competitors

$3.61 -0.21 (-5.50%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$3.60 0.00 (-0.14%)

As of 07:00 AM Eastern

Compare

ADAG vs. CADL, AURA, ALLO, PRME, and CRMD

Should you buy Adagene stock or one of its competitors? MarketBeat compares Adagene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adagene include Candel Therapeutics (CADL), Aura Biosciences (AURA), Allogene Therapeutics (ALLO), Prime Medicine (PRME), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.

How does Adagene compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Candel Therapeutics presently has a consensus target price of $18.57, suggesting a potential upside of 88.16%. Adagene has a consensus target price of $8.00, suggesting a potential upside of 121.61%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Candel Therapeutics has a beta of -0.52, meaning that its stock price is 152% less volatile than the broader market. Comparatively, Adagene has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Adagene has higher revenue and earnings than Candel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Adagene	$7.67M	22.30	-$17.61M	N/A	N/A

Adagene's return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Adagene	N/A	N/A	N/A

In the previous week, Candel Therapeutics had 3 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Candel Therapeutics and 1 mentions for Adagene. Adagene's average media sentiment score of 1.89 beat Candel Therapeutics' score of 1.03 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Candel Therapeutics	Positive
Adagene	Very Positive

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Adagene beats Candel Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Adagene compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Aura Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Adagene has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Adagene has higher revenue and earnings than Aura Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Adagene	$7.67M	22.30	-$17.61M	N/A	N/A

Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 192.86%. Adagene has a consensus target price of $8.00, suggesting a potential upside of 121.61%. Given Aura Biosciences' higher probable upside, equities research analysts clearly believe Aura Biosciences is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Adagene's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Adagene	N/A	N/A	N/A

In the previous week, Aura Biosciences had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Aura Biosciences and 1 mentions for Adagene. Adagene's average media sentiment score of 1.89 beat Aura Biosciences' score of 0.83 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Aura Biosciences	Positive
Adagene	Very Positive

Summary

Adagene beats Aura Biosciences on 9 of the 12 factors compared between the two stocks.

How does Adagene compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Adagene has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	31,926.38	-$190.89M	-$0.77	N/A
Adagene	$7.67M	22.30	-$17.61M	N/A	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Allogene Therapeutics presently has a consensus price target of $8.52, suggesting a potential upside of 360.66%. Adagene has a consensus price target of $8.00, suggesting a potential upside of 121.61%. Given Allogene Therapeutics' higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Adagene has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

In the previous week, Allogene Therapeutics had 2 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Allogene Therapeutics and 1 mentions for Adagene. Adagene's average media sentiment score of 1.89 beat Allogene Therapeutics' score of 1.19 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Allogene Therapeutics	Positive
Adagene	Very Positive

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Adagene	N/A	N/A	N/A

Summary

Adagene beats Allogene Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Adagene compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Adagene (NASDAQ:ADAG) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Adagene has higher revenue and earnings than Prime Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	135.37	-$201.14M	-$1.23	N/A
Adagene	$7.67M	22.30	-$17.61M	N/A	N/A

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Prime Medicine presently has a consensus price target of $7.53, suggesting a potential upside of 117.04%. Adagene has a consensus price target of $8.00, suggesting a potential upside of 121.61%. Given Adagene's stronger consensus rating and higher probable upside, analysts plainly believe Adagene is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Prime Medicine had 7 more articles in the media than Adagene. MarketBeat recorded 8 mentions for Prime Medicine and 1 mentions for Adagene. Adagene's average media sentiment score of 1.89 beat Prime Medicine's score of 0.97 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Prime Medicine	Positive
Adagene	Very Positive

Adagene has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Adagene's return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Adagene	N/A	N/A	N/A

Prime Medicine has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market. Comparatively, Adagene has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Summary

Adagene beats Prime Medicine on 10 of the 15 factors compared between the two stocks.

How does Adagene compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

CorMedix has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.08	$163.05M	$2.13	3.88
Adagene	$7.67M	22.30	-$17.61M	N/A	N/A

CorMedix has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Adagene has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

In the previous week, CorMedix had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Adagene. Adagene's average media sentiment score of 1.89 beat CorMedix's score of 0.86 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Positive
Adagene	Very Positive

CorMedix presently has a consensus price target of $14.86, indicating a potential upside of 79.65%. Adagene has a consensus price target of $8.00, indicating a potential upside of 121.61%. Given Adagene's stronger consensus rating and higher probable upside, analysts clearly believe Adagene is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

CorMedix has a net margin of 45.25% compared to Adagene's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Adagene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Adagene	N/A	N/A	N/A

34.2% of CorMedix shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CorMedix beats Adagene on 9 of the 15 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$181.01M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	N/A	20.98	26.94	24.38
Price / Sales	22.30	311.10	521.23	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	4.81	8.54	10.89	6.33
Net Income	-$17.61M	$23.83M	$3.59B	$331.02M
7 Day Performance	-5.74%	-2.77%	-1.53%	-0.33%
1 Month Performance	-0.82%	5.85%	2.72%	-1.29%
1 Year Performance	90.00%	52.15%	28.47%	21.30%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	2.6846 of 5 stars	$3.61 -5.5%	$8.00 +121.6%	+95.1%	$181.01M	$7.67M	N/A	260	Positive News Analyst Forecast
CADL Candel Therapeutics	3.3125 of 5 stars	$9.85 -1.8%	$18.00 +82.7%	+53.5%	$734.90M	N/A	N/A	60	Analyst Forecast
AURA Aura Biosciences	2.1789 of 5 stars	$7.03 -0.8%	$20.50 +191.6%	+3.7%	$733.01M	N/A	N/A	50	Analyst Downgrade
ALLO Allogene Therapeutics	2.382 of 5 stars	$2.15 +2.9%	$8.52 +296.4%	+43.4%	$721.37M	$20K	N/A	310
PRME Prime Medicine	3.1769 of 5 stars	$3.99 flat	$7.53 +88.8%	N/A	$720.66M	$4.63M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. CADL, AURA, ALLO, PRME, and CRMD

How does Adagene compare to Candel Therapeutics?

Summary

How does Adagene compare to Aura Biosciences?

Summary

How does Adagene compare to Allogene Therapeutics?

Summary

How does Adagene compare to Prime Medicine?

Summary

How does Adagene compare to CorMedix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. CADL, AURA, ALLO, PRME, and CRMD

How does Adagene compare to Candel Therapeutics?

Do analysts rate CADL or ADAG?

Which has more risk and volatility, CADL or ADAG?

Which has better earnings and valuation, CADL or ADAG?

Is CADL or ADAG more profitable?

Does the media refer more to CADL or ADAG?

Do insiders and institutionals hold more shares of CADL or ADAG?

Summary

How does Adagene compare to Aura Biosciences?

Which has more risk & volatility, AURA or ADAG?

Do institutionals and insiders hold more shares of AURA or ADAG?

Which has preferable earnings & valuation, AURA or ADAG?

Do analysts recommend AURA or ADAG?

Is AURA or ADAG more profitable?

Does the media refer more to AURA or ADAG?

Summary

How does Adagene compare to Allogene Therapeutics?

Which has stronger valuation & earnings, ALLO or ADAG?

Do institutionals & insiders hold more shares of ALLO or ADAG?

Do analysts recommend ALLO or ADAG?

Which has more risk and volatility, ALLO or ADAG?

Does the media refer more to ALLO or ADAG?

Is ALLO or ADAG more profitable?

Summary

How does Adagene compare to Prime Medicine?

Which has stronger earnings and valuation, PRME or ADAG?

Do institutionals & insiders hold more shares of PRME or ADAG?

Do analysts prefer PRME or ADAG?

Does the media refer more to PRME or ADAG?

Is PRME or ADAG more profitable?

Which has more volatility & risk, PRME or ADAG?

Summary

How does Adagene compare to CorMedix?

Which has higher earnings and valuation, CRMD or ADAG?

Which has more volatility and risk, CRMD or ADAG?

Does the media refer more to CRMD or ADAG?

Do analysts prefer CRMD or ADAG?

Is CRMD or ADAG more profitable?

Do institutionals and insiders believe in CRMD or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools